Article
Advances in Prognostic Methylation Biomarkers for Prostate Cancer
15 Oct 2020
Abstract excerpt
There is a major clinical need for accurate biomarkers for prostate cancer prognosis, to better inform treatment strategies and disease monitoring. Current clinically recognised prognostic factors, including prostate-specific antigen (PSA) levels, lack sensitivity and specificity in distinguishing aggressive from indolent disease, particularly in patients with localised intermediate grade prostate cancer. There...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
